MDNAF News and Press, Mandatum Pankki Oyj From 06/19/19

TORONTO and HOUSTON , June 19, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that Dr. Fahar Merchant, Chairman, President and CEO will present an overv...

Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma Canada NewsWire TORONTO and HOUSTON, June 18, 2019 - Disease control rate of up to 83% achieved; evidence of improved survival for patients TORONTO ...

Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results Canada NewsWire TORONTO and HOUSTON, June 13, 2019 TORONTO and HOUSTON , June 13, 2019 / CNW/ - Medicenna Therapeutics Corp.  (" Medicenna "...

TORONTO and HOUSTON , June 5, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will present preliminary top-line results from the recently completed Phas...

75% of IL4R +ve Patients Achieve Disease Control Following One Treatment With MDNA55 TORONTO and HOUSTON, TX , June 3, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company develop...

Medicenna to Present at the 9th Annual LD Micro Invitational Canada NewsWire TORONTO and HOUSTON, TX, May 30, 2019 TORONTO and HOUSTON, TX, May 30, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical st...

Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Canada NewsWire TORONTO and HOUSTON, May 16, 2019 TORONTO and HOUSTON , May 16, 2019 /CNW/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company "...

TORONTO and HOUSTON , May 1, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$757,940 (approximately, CD$1.02M) from the Cancer Prevention and Re...

Interim Top-Line Results to be Announced in June, 2019 TORONTO and HOUSTON , April 30, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has completed enro...

TORONTO , ON and HOUSTON, TX , April 23, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant, Chairman...